Syntec Optics Secures Over $4M in New BioMed Orders, Boosting Life Sciences Revenue
OPTX has more than doubled off its 52-week low of $1.18.
Summary
Syntec Optics secured over $4 million in new purchase orders for its BioMed products, expanding its presence across diversified life sciences platforms. This positive operational update follows the company's Q1 2026 report, which showed a net loss and revenue decline. The new orders contribute to future revenue and diversify the company's order book, building on a recent $2.4 million in space optics orders announced on June 16th. This demonstrates continued business momentum in a key segment.
At the time of this announcement, OPTX was trading at $12.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $487.8M. The 52-week trading range was $1.18 to $14.92. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.